Paramount Skydance is putting some billionaire weight behind its embattled bid for Warner Bros. Discovery. Yesterday, ...
The same global food system that is fueling rising obesity rates is also accelerating climate change, according to a sweeping ...
Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market ...
ZME Science on MSN
Obesity Patients Lost Nearly 30 percent of Their Body Weight on a New Experimental Drug and Many Saw Their Knee Pain Disappear
In a new clinical trial, people with obesity and knee osteoarthritis who took an experimental drug from Eli Lilly lost large ...
Until now, the most widely used GLP-1 medicines for weight loss have been injections. Novo Nordisk is pitching the newly approved Wegovy pill as a more convenient, once-daily option that could broaden ...
Novo Nordisk wins FDA approval for Wegovy in a pill, introducing first oral GLP-1 option for obesity
After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...
Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market.
Mortality rates are high in patients with type 1 diabetes, and overweight and obesity appear to be major factors, a speaker ...
Novo Nordisk has won the race to secure approval from the FDA for the first weight-loss drug to be administered orally ...
“Early intervention would be lifestyle change, and that can be extremely helpful, especially in younger adolescents who are ...
Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat ...
Global pharmaceutical leaders Eli Lilly and Novo Nordisk are intensifying competition in Indias rapidly expanding obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback